IP Library Granted Patent US 7,511,137
Granted Patent B2
US 7,511,137 · App. 11/016,403 · Granted Mar 31, 2009

Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,511,137
App. No.
11/016,403
Granted
Mar 31, 2009
Kind
B2
Abstract

The present invention provides stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino), 2-formamido cyclopentyl intermediates useful for the preparation of compounds having antiproliferative activity and methods to prepare the intermediates.

Claims (21)

1. A compound according to structural formula (I):

or a pharmaceutically acceptable salt or N-oxides thereof, wherein:

R 5 is halo, —CN, —NO 2 , CO 2 R a or —CF 3 ;

R a is selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl; and

LG is —S(O) 2 Me, —SMe,or a halide,

wherein the compound is enriched in one or more of the following stereoisomers according to structural formulae (II), (III) or (IV):

2. The compound of claim 1 in which R 5 is fluoro.

3. The compound of claim 1 in which R 5 is fluoro and LG is a halide.

4. A compound according to structural formula (II):

or a pharmaceutically acceptable salt or N-oxides therof, which is substantially free of the enantiomer and any diastereomers thereof, wherein R 5 and LG are as defined in claim 1 .

5. A compound according to structural formula (III):

or a pharmaceutically acceptable salt or N-oxides thereof, which is substantially free of the enantiomer and any diastereomers thereof wherein R 5 and LG are as defined in claim 1 .

6. A compound according to structural formula (IV):

or a pharmaceutically acceptable salt or N-oxides thereof, which is substantially free of the enantiomer and any diastereomers thereof wherein R 5 and LG are as defined in claim 1 .

7. The compound of any one of claims 4 - 6 in which R 5 is fluoro.

8. The compound of any one of claims 4 - 6 in which R 5 is fluoro and LG is a halide.

9. The compound of claim 1 in which a compound according to structural formula (I) is substantially free of a compound according to structural formula (V):

or a pharmaceutically acceptable salt or N-oxides thereof.

10. A compound according to structural formula (I) as defined in claim 9 which is enriched in one or more of the following stereoisomers according to structural formulae (II), (III) or (IV):

11. The compound of claim 9 or 10 in which R 5 is fluoro.

12. The compound of claims 9 or 10 in which R 5 is fluoro and LG is a halide.

Assignments (3)
SECURITY INTEREST Recorded May 8, 2026
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FUNDING IV TRUST
Reel/Frame 075576/0880 →
SECURITY INTEREST Recorded Aug 25, 2022
From: RIGEL PHARMACEUTICALS, INC.
To: MIDCAP FINANCIAL TRUST
Reel/Frame 061327/0712 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 17, 2006
From: LI, HUI
To: RIGEL PHARMACEUTICALS, INC.
Reel/Frame 017481/0151 →